TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10728365

Group type: EXPERIMENTAL
Intervention: 2 I.U. of recombinant human growth hormone (GH) for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8957033

Group type: EXPERIMENTAL
Intervention: Enalapril (n = 34)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional antihypertensive drugs (n = 35)
Number of subjects: 69
Study: 1554449

Group type: EXPERIMENTAL
Intervention: Nasal dilator
Number of subjects: 11
Study: 3575131

Group type: EXPERIMENTAL
Intervention: 10 mg i.m. of Phytonadione (Konakion, Roche) administered on the initial day of GFD
Number of subjects: 37

Group type: COMPARATOR
Intervention: No vitamin K administration (Control group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Both groups (Vitamin K and Control)
Number of subjects: 37
Study: 31327235

Group type: EXPERIMENTAL
Intervention: Positive staff-resident interactions
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Neutral staff-resident interactions
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Negative staff-resident interactions
Number of subjects: 341
Study: 31106951

Group type: EXPERIMENTAL
Intervention: Blunt punch
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Serrated punch
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sharp punch
Number of subjects: 10
Study: 26733351

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (one ComProbi capsule containing L. rhamnosus a day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (one capsule of placebo a day)
Number of subjects: 66
Study: 26095854

Group type: EXPERIMENTAL
Intervention: HRV biofeedback‐assisted relaxation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 25454870

Group type: EXPERIMENTAL
Intervention: Vaccine, IL-2, GM-CSF and rhGH (n=3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vaccine alone (n=4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IL-2, GM-CSF and rhGH (n=5)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 12
Study: 22965757

Group type: EXPERIMENTAL
Intervention: High PUFA diet (P/S ratio 2:1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low PUFA diet (P/S ratio 0.5:1)
Number of subjects: 16
Study: 19201650

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily) and bevacizumab (15 mg/kg every 3 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Erlotinib and bevacizumab
Number of subjects: 48
Study: 17429343

Group type: EXPERIMENTAL
Intervention: On-line hemofiltration
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-flux hemodialysis (HF-HD)
Number of subjects: 15
Study: 15075311

Group type: EXPERIMENTAL
Intervention: Unilateral resistance training (training intensities of at least 50% of maximal voluntary strength for a minimum of 2 weeks)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Unilateral resistance training
Number of subjects: 17
Study: 11269613

Group type: EXPERIMENTAL
Intervention: Beef protein (43 g for women and 50 g for men daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Plant protein (equal amount of protein from legumes, nuts, and grains)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Self-selected prestudy diets
Number of subjects: 23
Study: 9464712

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (60 g daily containing 40 g of isolated soy protein)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (casein, 60 g daily)
Number of subjects: 104
Study: 7646157

Group type: EXPERIMENTAL
Intervention: Autologous tissue cardiac valve implantation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Echocardiographic examination
Number of subjects: 30
Study: 2654791

Group type: EXPERIMENTAL
Intervention: AAT (amsacrine, cytarabine, thioguanine)
Number of subjects: 69

Group type: COMPARATOR
Intervention: DAT (daunorubicin, cytarabine, thioguanine)
Number of subjects: 69
Study: 794897

Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-tryptophan (8 g daily)
Number of subjects: 0
Study: 30537411

Group type: EXPERIMENTAL
Intervention: Continuous exercise training (CONT; n = 17; 70% of peak heart rate)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Interval exercise training (INT; n = 14; 3 min at 50% of peak heart rate and 3 min at 90% of peak heart rate)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both CONT and INT training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Exercise dose (kilocalories per session)
Number of subjects: 31
Study: 28295869

Group type: EXPERIMENTAL
Intervention: CRT programmed on (CRT-on)
Number of subjects: 1591

Group type: COMPARATOR
Intervention: CRT programmed off (CRT-off)
Number of subjects: 1591
Study: 25185469

Group type: EXPERIMENTAL
Intervention: Video-based coaching by a surgeon using the GROW coaching model
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group viewing online surgical lectures
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Video-based coaching
Number of subjects: 20
Study: 23558043

Group type: EXPERIMENTAL
Intervention: ivabradine (5 mg twice daily)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ranolazine (375 mg twice daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study: 22010346

Group type: EXPERIMENTAL
Intervention: Tangshen Formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tangshen Formula + Conventional western medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional western medicine
Number of subjects: 0
Study: 19828704

Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 356

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Matched sibling donor
Number of subjects: 356

Group type: COMPARATOR
Intervention: No matched sibling donor
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Relapsed patients
Number of subjects: 356

Group type: COMPARATOR
Intervention: Complex cytogenetic abnormalities
Number of subjects: 356

Group type: COMPARATOR
Intervention: CNS involvement at diagnosis
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: CD1a positivity
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Lack of CD13 expression
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: NOTCH1 mutations
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: CDKN2A mutations
Number of subjects: 356
Study: 16914703

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg)
Number of subjects: 201
Study: 14999637

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (800 mg every day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxandrolone (10 mg twice per day)
Number of subjects: 0
Study: 11824370

Group type: EXPERIMENTAL
Intervention: Local and systemic application of growth factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental research on growth factors
Number of subjects: 0
Study: 9238874

Group type: EXPERIMENTAL
Intervention: SnF2 dentifrice (Crest Plus Gum Care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NaF dentifrice (Crest)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baking soda/peroxide dentifrice (Mentadent)
Number of subjects: 0
Study: 8491302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2 mg terbutaline
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 4 mg terbutaline
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 6 mg terbutaline
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All doses of terbutaline (2, 4, 6 mg)
Number of subjects: 17
Study: 6366126

Group type: EXPERIMENTAL
Intervention: Carbenicillin (or ticarcillin) plus amikacin
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Carbenicillin (or ticarcillin) plus amikacin plus cefazolin
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Any oral intestine decontamination regimen
Number of subjects: 841
Study: 31787506

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 28206715

Group type: EXPERIMENTAL
Intervention: Housing First
Number of subjects: 470

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 470
Study: 27005498

Group type: EXPERIMENTAL
Intervention: Low lactose milk powder feeding in treatment group (64 cases)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Conventional treatment (rehydration, correction of acidosis, oral smecta, intestinal probiotics) in control group (60 cases)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Low lactose milk powder feeding in treatment group
Number of subjects: 311

Group type: COMPARATOR
Intervention: Conventional treatment in control group
Number of subjects: 311
Study: 25102239

Group type: EXPERIMENTAL
Intervention: Single and double leg drop jumps from a range of heights that equalized loading per leg.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Equalizing loading by impulse per leg.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 minute coaching session for consistent drop height.
Number of subjects: 14
Study: 22033742

Group type: EXPERIMENTAL
Intervention: Uncertainty reduction intervention (IC)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Usual care clinics (UCC)
Number of subjects: 665
Study: 20073409

Group type: EXPERIMENTAL
Intervention: 80 mg of daily OxyContin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 160 mg of daily OxyContin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 240 mg of daily OxyContin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Normalized values using the algorithm
Number of subjects: 36
Study: 16765063

Group type: EXPERIMENTAL
Intervention: Posthypnotic suggestion to perceive input stream as meaningless symbols
Number of subjects: 0

Group type: COMPARATOR
Intervention: No posthypnotic suggestion
Number of subjects: 0
Study: 16962929

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14982753

Group type: EXPERIMENTAL
Intervention: Severe diabetes (SD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mild diabetes (MD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nondiabetic (ND)
Number of subjects: 28
Study: 11310245

Group type: EXPERIMENTAL
Intervention: 20% Buckley's Formocresol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Calcium Hydroxide
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (F and C)
Number of subjects: 52
Study: 8548465

Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix 320; 40 to 240 mL, mean 141 mL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ioversol (Optiray 320; 20 to 180 mL, mean 87 mL)
Number of subjects: 48
Study: 1808526

Group type: EXPERIMENTAL
Intervention: Epidural steroid injections with Depo‐Medrol or Polcortolon plus bupivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural steroid injections with Polcortolon plus bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 30
Study: 6419595

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 31778446

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg/day for 16 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low-dose oral isotretinoin 0.3-0.4 mg/kg for 16 weeks
Number of subjects: 39
Study: 30327236

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Sequential or radiotherapy alone
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 107
Study: 28807086

Group type: EXPERIMENTAL
Intervention: Oral steroids followed by intranasal steroids (Group A)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Oral steroids alone (Group B)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Watchful waiting (Group C)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 290
Study: 25870079

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 759

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 759
Study: 24229669

Group type: EXPERIMENTAL
Intervention: Basal insulin therapy (including a single injection of basal insulin and basal insulin plus preprandial insulin)
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Premixed insulin therapy
Number of subjects: 1086
Study: 20642328

Group type: EXPERIMENTAL
Intervention: Support group participation (12 monthly support group meetings)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Support group participation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 49
Study: 19542400

Group type: EXPERIMENTAL
Intervention: Low-dose unenhanced CT
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard-dose i.v. contrast-enhanced CT
Number of subjects: 207
Study: 16942934

Group type: EXPERIMENTAL
Intervention: Subjects with the most common genotype combination of SNPs (‐604G/A, ‐501A/C, Leu72Met, Gln90Leu)
Number of subjects: 522
Study: 15501741

Group type: EXPERIMENTAL
Intervention: Valium (0.1 mg/kg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (50 mg/kg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Valium (0.1 mg/kg) and Magnesium sulfate (50 mg/kg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (neither valium nor magnesium sulfate)
Number of subjects: 240
Study: 10785910

Group type: EXPERIMENTAL
Intervention: Intensive training group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Home exercise group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 9366103

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/hydrochlorothiazide 12.5 mg
Number of subjects: 188

Group type: COMPARATOR
Intervention: Captopril 50 mg/hydrochlorothiazide 25 mg
Number of subjects: 188
Study: 8222202

Group type: EXPERIMENTAL
Intervention: Saphenous vein (SV) coronary grafts
Number of subjects: 349
Study: 2931040

Group type: EXPERIMENTAL
Intervention: Procaterol metered-dose inhaler
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30809776

Group type: EXPERIMENTAL
Intervention: Fresh red blood cells (7 days or less)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Standard red blood cells
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Fresh red blood cells
Number of subjects: 217
Study: 29749935

Group type: EXPERIMENTAL
Intervention: Fusion-optimized intervals (FOI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Nominal settings
Number of subjects: 180
Study: 26930241

Group type: EXPERIMENTAL
Intervention: 5-session DV prevention program (active condition)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Health class as usual (waitlist control condition)
Number of subjects: 225
Study: 25300431

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 34
Study: 22624978

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partially whey hydrolyzed formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extensively hydrolyzed whey formula
Number of subjects: 0
Study: 19910797

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 0
Study: 18929702

Group type: EXPERIMENTAL
Intervention: Thienopyridine therapy continued beyond 1 year
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Thienopyridine therapy discontinued after 1 year
Number of subjects: 2736
Study: 16385904

Group type: EXPERIMENTAL
Intervention: Generic candidates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified method by Chow and Shao (1997)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study: 11431603

Group type: EXPERIMENTAL
Intervention: Nasal insulin administration (gelified form)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Subcutaneous regular insulin injections
Number of subjects: 16
Study: 9876229

Group type: EXPERIMENTAL
Intervention: PMA stimulation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ZX stimulation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Resting cells
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PMA and ZX stimulation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Serum concentrations of interleukin-6
Number of subjects: 56
Study: 8027276

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate (nasal spray)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buserelin acetate (nasal spray)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buserelin acetate
Number of subjects: 0
Study: 2513939

Group type: EXPERIMENTAL
Intervention: Three days' treatment with co-trimoxazole 960 mg twice a day
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Seven days' treatment with co-trimoxazole 960 mg twice a day
Number of subjects: 327
Study: 788001

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Loxapin
Number of subjects: 40
Study: 31705450

Group type: EXPERIMENTAL
Intervention: Boiled dill seed (10 g boiled in 100 mL for 10 min, given orally at the beginning of active phase)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin (10 IU in 1000 mL of Ringer solution)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Boiled dill seed
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 100
Study: 30427243

Group type: EXPERIMENTAL
Intervention: Heat training combined with 'LHTL' hypoxia (H+H; FiO2 = 14.4% [3000 m], 13 h·d‐1; train at <600 m, 33°C, 55% relative humidity [RH])
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Heat training (HOT; live and train <600 m, 33°C, 55% RH)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Temperate training (CONT; live and train <600 m, 13°C, 55% RH)
Number of subjects: 25
Study: 27320685

Group type: EXPERIMENTAL
Intervention: PDL-only treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PDL + rapamycin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PDL + Erbium YAG laser ablation + rapamycin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: rapamycin monotherapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PDL + Erbium YAG + rapamycin
Number of subjects: 14
Study: 25399948

Group type: EXPERIMENTAL
Intervention: Shortened (46 weeks), intensified therapy
Number of subjects: 147
Study: 23221935

Group type: EXPERIMENTAL
Intervention: 1500 mg/day of encapsulated WGOE
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 21288608

Group type: EXPERIMENTAL
Intervention: Cooperative learning method
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional learning method
Number of subjects: 34
Study: 18649754

Group type: EXPERIMENTAL
Intervention: Cernilton 750 mg, twice a day for 4 years
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cernilton 375 mg, twice a day for 4 years
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cernilton 750 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cernilton 375 mg
Number of subjects: 240
Study: 17050212

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No drugs (baseline)
Number of subjects: 0
Study: 12949664

Group type: EXPERIMENTAL
Intervention: Vozraston
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 34
Study: 10978253

Group type: EXPERIMENTAL
Intervention: Vitamin E (182 mg of RRR‐alpha‐tocopherol acetate per day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg of slow release ascorbate per day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of vitamin E and C
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8774056

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 1346413

Group type: EXPERIMENTAL
Intervention: Clindamycin (300 mg twice daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 84
Study: 6593316

Group type: EXPERIMENTAL
Intervention: 100 rad X 18 cranial radiation therapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: 180 rad X 10 cranial radiation therapy
Number of subjects: 97
Study: 30885073

Group type: EXPERIMENTAL
Intervention: Ertapenem (one dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ampicillin, gentamicin, and clindamycin (AGC-1, one-time intravenous dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ampicillin, gentamicin, and clindamycin (AGC-24, 24-hour coverage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 0
Study: 29477099

Group type: EXPERIMENTAL
Intervention: Removable offloading device
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Removable offloading device (adherent patients)
Number of subjects: 31
Study: 27234302

Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity Internet Intervention
Number of subjects: 205

Group type: COMPARATOR
Intervention: Wellness Contact Control Internet Group
Number of subjects: 205
Study: 25697490

Group type: EXPERIMENTAL
Intervention: Sun protection text messages
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Skin self-examination text messages
Number of subjects: 546

Group type: COMPARATOR
Intervention: Attention-control text messages
Number of subjects: 546
Study: 23067340

Group type: EXPERIMENTAL
Intervention: Intracardiac ultrasound (ICE) imaging
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional electroanatomic mapping
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ablation energy delivery outside the greatest esophagus anatomy borders
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Follow-up after 12 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Post-ablation observation
Number of subjects: 50